Smart Immune, a clinical-stage biotechnology company, has recently achieved a major breakthrough by developing an innovative bioproduction method for cultivating T-cell progenitors. Smart Immune is now seeking a Chimeric Antigen Receptor (CAR) construct, that enables precise recognition of tumour antigens, to develop a groundbreaking CAR-T Cell therapy for the treatment of haematological and/or solid tumour malignancies.
Approaches of Interest:
Technology
Academic Researcher
Centre of Excellence
Research Project
Spinout Company
Technology
Academic Researcher
Centre of Excellence
Research Project
Spinout Company
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.